Dodecanoic acid (DDA), a medium chain saturated fatty acids, has been reported to have anticancer activity in reproductive system cancer and some digestive tract cancers. However, the role and the underlying mechanism of DDA in liver cancer have been rarely defined.
Mouse liver cancer Hepa 1–6 cells were administrated with DDA in this present study. Apoptosis, cell cycle analysis, mitochondrial membrane potential (MMP) and ATP content were determined by flow cytometry; GSH availability, ROS level and SOD activity was assessed by a microplate reader; Bcl-2, Bax and Caspase-3 protein levels were analyzed by western blot.
0.5 mM DDA was identified as the ideal concentration for investigation and could time-dependently inhibit cell viability. DDA-treated cells had a significant, time-dependent increase in cell apoptotic rate in spite of an accumulation of the cells in S + G2/M phase of the cell cycle. The enhanced level of ROS, depletion of GSH and the reduced activity of SOD in DDA-treated cells indicated the generation of oxidative stress; mitochondrial dysfunction was evidenced by the dissipation of MMP of and the reduction in ATP content. Cell death via mitochondrial pathway was indicated by the reduced Bcl-2/Bax ratio and the increased level of caspase-3 protein.
Taken together, DDA effectively triggers oxidative stress-induced death in liver cancer cells by disturbing the structure and function of mitochondria. The findings provide an in-depth insight into the potential action mechanism of DDA on liver cancer.
Figure 1
Figure 1
Figure 1
Figure 1
Figure 2
Figure 2
Figure 2
Figure 2
Figure 3
Figure 3
Figure 3
Figure 3
Figure 4
Figure 4
Figure 4
Figure 4
Figure 5
Figure 5
Figure 5
Figure 5
Figure 6
Figure 6
Figure 6
Figure 6
Figure 7
Figure 7
Figure 7
Figure 7
Figure 8
Figure 8
Figure 8
Figure 8
Loading...
Posted 01 Dec, 2020
Posted 01 Dec, 2020
Dodecanoic acid (DDA), a medium chain saturated fatty acids, has been reported to have anticancer activity in reproductive system cancer and some digestive tract cancers. However, the role and the underlying mechanism of DDA in liver cancer have been rarely defined.
Mouse liver cancer Hepa 1–6 cells were administrated with DDA in this present study. Apoptosis, cell cycle analysis, mitochondrial membrane potential (MMP) and ATP content were determined by flow cytometry; GSH availability, ROS level and SOD activity was assessed by a microplate reader; Bcl-2, Bax and Caspase-3 protein levels were analyzed by western blot.
0.5 mM DDA was identified as the ideal concentration for investigation and could time-dependently inhibit cell viability. DDA-treated cells had a significant, time-dependent increase in cell apoptotic rate in spite of an accumulation of the cells in S + G2/M phase of the cell cycle. The enhanced level of ROS, depletion of GSH and the reduced activity of SOD in DDA-treated cells indicated the generation of oxidative stress; mitochondrial dysfunction was evidenced by the dissipation of MMP of and the reduction in ATP content. Cell death via mitochondrial pathway was indicated by the reduced Bcl-2/Bax ratio and the increased level of caspase-3 protein.
Taken together, DDA effectively triggers oxidative stress-induced death in liver cancer cells by disturbing the structure and function of mitochondria. The findings provide an in-depth insight into the potential action mechanism of DDA on liver cancer.
Figure 1
Figure 1
Figure 1
Figure 1
Figure 2
Figure 2
Figure 2
Figure 2
Figure 3
Figure 3
Figure 3
Figure 3
Figure 4
Figure 4
Figure 4
Figure 4
Figure 5
Figure 5
Figure 5
Figure 5
Figure 6
Figure 6
Figure 6
Figure 6
Figure 7
Figure 7
Figure 7
Figure 7
Figure 8
Figure 8
Figure 8
Figure 8
Loading...